Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Einstein CYP cohort study
2008-003303-31Phase 2Completed
- Sponsor
- Bayer
- Start
- Nov 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rivaroxaban in deep vein thrombosis (DVT), pulmonary embolism (PE) and venous thromboembolism (VTE), sponsored by Bayer. Primary endpoints: Population pharmacokinetics of rivaroxaban and Population pharmacodynamics of adapted rivaroxaban regimen. Started Nov 2008; status: completed.
02
Drugs
rivaroxaban
03
Conditions
deep vein thrombosis (DVT)pulmonary embolism (PE)venous thromboembolism (VTE)
Beyond the preview
Go deeper on 2008-003303-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003303-31.